Optical Coherence Tomography (OCT) has been shown to have great success in determining whether or to provide additional treatments of Avastin to patients suffering from wetmacular degeneration. A study published in Ophthalmologe on July 19, 2008 reported the success of using OCT as the basis of deciding to provide additional treatments of Avastin to those patients diagnosed with wet macular degeneration.
In the study, thirty-two patients were treated with a single injection of Avastin, and were reinjected based on the results of an OCT examination.
After just a single injection, 74 percent of the patients deomonstrated complete retinal fluid absorption, with 44 percent of the patients showing no relapse during an average follow-up period of 30 weeks. A second injection was required by 56 percent of the patients studied after an average of 19 weeks, with 82 percent of these patients showing absorption of the macular fluid with regain of their previous visual acuity.
Of the 26 percent of the patients that showed no improvement in their age-related macular degeneration after their first treatment, 44 percent of those patients demonstrated improvement after their second injection of Avastin.
The amazing statistic is that all patients showed stabilisation of visual acuity during follow-up, with approximately 30 percent showing a gain of 3 lines on a visual acuity chart. Similar improvements had been reported by other studies examining the abilty of Avastin to treat wet macular degeneration.
As a result of the study, the researchers were able to conculde that OCT-based injections of Avastin for wet macular degeneration were reduced.
This not only lowers the cost of treatments to health care systems, but also limits the patients’ exposure to invasive injections into the eye when having their macular degeneration treated with Avastin.
Source: Ophthalmologe. 2008 Jul 19